SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Perspectives in Vascular Surgery and Endovascular Therapy
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Ricotta, J. J.
Right arrow Articles by Harris, L. M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ricotta, J. J.
Right arrow Articles by Harris, L. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Current Status Of Cryopreserved Saphenous Vein Homografts

John J. Ricotta, M.D.

Department of Surgery, State University of New York, Stony Brook, NY

Linda M. Harris, M.D.

Department of Surgery, State University of New York School of Medicine and Biomedical Sciences, Kaléida Health System, Millard Fillmore Gates Hospital, Buffalo, NY

The lack of suitable autogenous tissue and the easy availability of cryopreserved allograft veins have recently led to increased utilization of allograft bypasses. Improved methods of cryopreservation have been shown to maintain integrity of the endothelial and smooth muscle cell layers prior to implantation, increasing enthusiasm for the vein bank. However, after implantation, immune reactions result in eventual cell death and fibrosis of the conduit, with poor long-term patency. Attempts at modification of the immune response are preliminary and suggest a potential for improved patency. However, long-term patency remains poor, with only 19 to 42% of grafts patent at 2 years. Current use of the cryopreserved allograft vein should be limited to distal bypass for limb salvage in the absence of suitable autogenous tissue or revascularization for limb-threatening ischemia in an infected field in the absence of suitable autogenous tissue.

Key Words: Allograft • cryopreservation

Perspectives in Vascular Surgery and Endovascular Therapy, Vol. 12, No. 1, 123-132 (1999)
DOI: 10.1177/153100359901200119
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




Advertisement